From MS to NMOSD to early Alzheimer's disease, neurologic mAbs are delivering proven clinical benefit. But as efficacy becomes less of a differentiator, what determines whether these therapies reach patients? In this art...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
June 2026 Medical/ Commercial Pulse Check
With the first EU JCAs finalized and CMS extending deadlines for its ambitious Medicaid international-pricing model, ICON and other industry leaders share how they are navigating the friction between global harmonization and local execution including the practical evolution of global pricing floors, the maturing role of AI agents, and the new reality of European access.
-
The impact of drug pricing and reimbursement on the pharmaceutical industry
Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. Companies must consider price and reimbursement across multiple countries, act early in the development cycle and ensure the evidence required to support their commercial strategy is built into their development plans.
-
ICON experts tackle specialty drug access challenges at AXS24
In this article, Angela Lawrence, Senior Director of RWE, Joe Brown, Principal Medical and Market Research, and Mark McCoy, RPh, MBA, Director Market Access and Reimbursement discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
-
Data doesn't cut it - Payer engagement requires a humanistic approach
A drug’s ability to reach the market is essential; however, pharma manufacturers have struggled to meet the increased pressure to demonstrate the value of their drugs, particularly in therapeutic areas over-populated with treatment options. Data surrounding the success and efficacy of a drug are rarely sufficient to convince stakeholders that the drug is worth the investment. Payers have displayed a need for a more humanistic approach, and against this backdrop, manufacturers need to reconsider their engagement strategies.
-
Health technology assessments: understanding the global landscape and considerations for drug development
Manpreet Sidhu and Ben Cieply share insights on how HTAs inform decisions for market access and reimbursement of new pharmacotherapies.
